mCSF-RGD-HSA

mCSF-RGD-HSA (also known as M-CSFRGD-HSA) is a recombinant bispecific fusion protein consisting of a mutated macrophage colony-stimulating factor (M-CSF) containing an RGD motif, fused to human serum albumin (HSA) to extend its serum half-life. Developed by researchers at Ben-Gurion University of the Negev, mCSF-RGD-HSA acts as a dual antagonist targeting both the colony-stimulating factor 1 receptor (CSF1R, also known as c-Fms) and integrin alpha-V/beta-3 (αvβ3). By blocking c-Fms, it inhibits osteoclast differentiation, and by blocking αvβ3 integrin, it inhibits osteoclastic bone resorption. This dual-targeting mechanism allows mCSF-RGD-HSA to reduce osteoclast activity and prevent bone loss without completely shutting down bone formation, making it a promising therapeutic candidate for osteoporosis, cherubism, and other aggressive osteoclast-mediated bone loss disorders.

Other names

HSA-conjugated M-CSFRGD proteinM-CSFRGD-human serum albumin fusion proteinhuman serum albumin-conjugated M-CSFRGD protein